Manila Bulletin
Sinovac assures safety, efficacy, affordability of its vaccine
Sinovac Biotech general manager Helen Yang expressed confidence in the safety profile of CoronaVac, stating that no serious adverse reactions have been reported so far.
She assured that the vaccine meets World Health Organization standards and will be provided at an affordable price in the Philippines.
Yang highlighted that Sinovac uses inactivation technology, which has a proven safety record in vaccine development.
The most common side effect reported in clinical trials is mild pain at the injection site, affecting about 20% of participants, with fever being the highest reported side effect comparable to other vaccines.
Sinovac and the Philippine government have signed a term sheet for 25 million doses, with 50,000 doses eyed for delivery in February.
CoronaVac is still awaiting emergency use authorization from the Philippines' Food and Drug Administration.
Vaccine czar Carlito Galvez Jr. clarified that the procurement of Sinovac is not yet finalized amidst some skepticism regarding its efficacy and cost.
Topics in this story
Explore more stories about these topics.
🤖
This story was generated by AI to help you understand the key points. For more detailed coverage, please see the news articles from trusted media outlets below.
News Sources
See how different news organizations are covering this story. Below are the original articles from various Philippine news sources that contributed to this summary.
Malacañang denied claims that the Sinovac COVID-19 vaccine costs PHP3,600 per dose, stating the actual price is significantly lower.
+1
Read more →
Presidential Spokesperson Harry Roque claims reports of Sinovac vaccines being the most expensive are orchestrated by "ignorant" government critics.
Read more →
Senators Francis Pangilinan and Juan Miguel Zubiri expressed doubts regarding the efficacy of China's Sinovac COVID-19 vaccine.
Read more →
Chinese pharmaceutical company Sinovac has submitted an application for emergency use authorization (EUA) to the Philippine Food and Drug Administration (FDA).
Read more →
The Food and Drug Administration (FDA) has approved Sinovac Biotech's application to conduct clinical trials for its COVID-19 vaccine in the Philippines.
Read more →